U.S. Markets close in 4 hrs 43 mins

Alimera Sciences, Inc. (ALIM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.32+0.02 (+1.54%)
As of 11:15AM EDT. Market open.
People also watch
PSDVACRXANTHAPRIEVOK

Alimera Sciences, Inc.

6120 Windward Parkway
Suite 290
Alpharetta, GA 30005
United States
678-990-5740
http://www.alimerasciences.com

SectorHealthcare
IndustryDrug Manufacturers - Major
Full Time Employees125

Key Executives

NameTitlePayExercisedAge
Mr. Charles Daniel MyersCo-Founder, Chief Exec. Officer and Director654.39kN/A63
Mr. Richard S. Eiswirth Jr.Pres and Chief Financial Officer517.85kN/A49
Dr. Kenneth Green Ph.D.Chief Scientific Officer, Global Head of R&D and Sr. VP454.01kN/A59
Mr. David R. HollandCo-Founder and Sr. VP of Sales & MarketingN/AN/A53
Mr. Jeffrey W. BurrisVP, Gen. Counsel and Sec.N/AN/A45
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient’s eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has an agreement with pSivida US, Inc. for the development and sale of ILUVIEN, and a delivery device to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans other than uveitis or to treat DME. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.

Corporate Governance

Alimera Sciences, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 9. The pillar scores are Audit: 5; Board: 2; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.